Is There An Opportunity With ResMed Inc.'s (NYSE:RMD) 31% Undervaluation?

Published on 11 Jan 2025 on Simply Wall St. · via Yahoo Finance

In this calculation we've used 6.5%, which is based on a levered beta of 0.946. Beta is a measure of...

Read the rest of the article

Start tracking your investments with Statfolio

Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to...

Zacks · via Yahoo Finance 23 Jan 2025

Zacks Rank We also need to consider the stock's Zacks Rank, as this supersedes any trend on the...

Zacks · via Yahoo Finance 22 Jan 2025

For the full year, the company currently expects an adverse impact of 75 basis points from foreig...

Zacks · via Yahoo Finance 21 Jan 2025

Key Picks Some better-ranked stocks in the broader medical space are Veracyte VCYT, Omnicell OMCL...

Zacks · via Yahoo Finance 21 Jan 2025

For Align Technology ALGN, we remain concerned about the current economic uncertainty, which...

Zacks · via Yahoo Finance 16 Jan 2025

Henry Schein, Inc. HSIC recently completed the acquisition of substantially all of the assets of...

Zacks · via Yahoo Finance 16 Jan 2025

It delivered an earnings surprise of 29.33%, on average, for the past four quarters. GS is slated...

Zacks · via Yahoo Finance 15 Jan 2025

The fourth-quarter 2024 earnings season will kick off this week, with banking sector players due ...

Zacks 13 Jan 2025

Revvity, Inc. RVTY announced the receipt of the FDA’s 510(k) clearance for EUROIMMUN’s automated...

Zacks · via Yahoo Finance 13 Jan 2025

In this calculation we've used 6.5%, which is based on a levered beta of 0.946. Beta is a measure...

Simply Wall St. · via Yahoo Finance 11 Jan 2025